Institutional members access full text with Ovid®

Share this article on:

Maternal Buprenorphine Treatment and Fetal Neurobehavioral Development

Jansson, L.M.; Velez, M.; McConnell, K.; Spencer, N.; Tuten, M.; Jones, H.E.; King, V.L.; Gandotra, N.; Milio, L.A.; Voegtline, K.; DiPietro, J.A.

Obstetric Anesthesia Digest: March 2018 - Volume 38 - Issue 1 - p 43
doi: 10.1097/01.aoa.0000530008.76097.57
Mother, Fetus, Neonate

(Am J Obstet Gynecol. 2017;216(5):529.e1–529.e8)

Opioid usage is increasing among pregnant mothers in the United States, which can lead to neonatal abstinence syndrome in their children. Previous studies have shown less severe neonatal abstinence syndrome in infants whose mothers were treated for opioid use with buprenorphine rather than methadone. This study looked at the effects of buprenorphine on fetal activity and development.

Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved